Outcomes of Hodgkin's Lymphoma Patients with Relapse or Progression following Autologous Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 3, 2012, Pages 451-457

  Kaloyannidis, Panayotis ^a   Voutiadou, Georgia ^a   Baltadakis, Ioannis ^b   Tsirigotis, Panagiotis ^c   Spyridonidis, Alexandros ^d   Repousis, Panagiotis ^e   Balta, Artemisia ^b   Tsimberis, Simeon ^a   Karakasis, Dimitrios ^b   Sakellari, Ioanna ^a   Dervenoulas, Ioannis ^c   Harhalakis, Nicholas ^b   Anagnostopoulos, Achilles ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^e METAXA CANCER HOSPITAL   (Greece)

Author keywords

Autologous hematopoietic cell transplantation; Hodgkin's lymphoma; Relapse

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856951375     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.020     Document Type: Article

References (24)

1. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BLNI randomized trial. Lancet 1993, 341:1051-1054.
2. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapse chemosensensitive Hodgkin's disease: a randomized trial. Lancet 2002, 359:2065-2071.
3. Milpied N., Fielding A.K., Pearce R.M., Ernst P., Goldstone A.H. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. JClin Oncol 1996, 14:1291-1296.
4. Shamash J., Lee S.M., Radford J.A., et al. Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. Ann Oncol 2000, 11:715-771.
5. Paltiel O., Rubinstein C., Or R., et al. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant 2003, 31:565-569.
6. Sureda A., Constans M., Iriondo A., et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005, 16:625-633.
7. Bierman P.J., Lynch J.C., Bociek R.G., et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002, 13:1370-1377.
8. Vose J.M., Bierman P.J., Anderson J.R., et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992, 80:2142-2148.
9. Varterasian M., Ratanatharathorn V., Uberti J.P., et al. Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation. Leuk Lymphoma 1995, 20:59-65.
10. Spenser A., Reed K., Artur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 2007, 37:760-766.
11. Oki Y., Pro B., Fayad L.E., et al. A phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008, 112:831-836.
12. Kuruvilla J., Song K., Mollee P., et al. A phase II study of thalidomide and vinvlastine for patients with Hodgkin's disease. Hematology 2006, 11:25-29.
13. Todisco E., Castagna L., Sarina B., et al. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell transplantation. Eur J Haematol 2007, 78:322-329.
14. Thomson K.J., Peggs K.S., Smith P., et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008, 41:765-770.
15. Peggs K.S., Hunter A., Chopra R., et al. Clinical evidence of a graft-versus-Hodgkin's lymphoma effect after reduced intensity allogeneic transplantation. Lancet 2005, 365:1934-1941.
16. Lin T.S., Avalos B.R., Penza S.L., Marcucci G., Elder P.J., Copelan E.A. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplant 2002, 29:763-767.
17. Smith S.M., van Besien K., Carreras J., et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008, 14:904-912.
18. Moskowitz A.J., Perales M.A., Kewalramani T., et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009, 146:158-163.
19. Crump M. Management of Hodgkin Lymphoma in relapse after autologous stem cell transplantation. Hematology Am Soc Hematol Educ Program 2008, 326-333.
20. Gallamini A., Hutchings M., Rigacci L., et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007, 25:3746-3752.
21. Lambert R.J., Bomanji B.J., Peggs K.S., et al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood 2010, 115:2763-2768.
22. Hutchings M., Mikhaeel N.G., Fields P.A., Nunan T., Timothy A.R. Prognostic value of interim FDG-PET after two or 3 cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005, 16:1160-1168.
23. Sher D.J., Mauch P.M., van den Abbeele A., LaCasce A.S., Czerminsci J., Ng A.K. Prognostic significance of mid- or post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol 2009, 20:1848-1853.
24. Palmer J., Goggins T., Broadwater G., et al. Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing au to-SCT in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2011, 46:847-851.